oncolytic VSV-GP BI 1821736
Term · Oncology and biomedicine · MLC-T-ONC-015668
An oncolytic virus derived from the vesicular stomatitis virus (VSV), a single-stranded RNA virus, and containing a genetically modified glycoprotein (GP) and a human CD80 (B7.1) Fc fragment, with potential immunomodulating and antineoplastic activities. Upon administration, oncolytic VSV-GP BI 1821736 preferentially replicates in tumor cells, and induces VSV-mediated cytolytic activity towards the tumor cells. Viral infection also stimulates the immune system to recognize these same tumor cells, leading to immune-mediated killing of both infected and non-infected tumor cells, thereby further killing tumor cells. In addition, BI 1821736 secretes CD80, which targets and binds to CD28, and in the presence of antigenic T-cell receptor (TCR) signaling leads to the co-stimulation of T-cell responses including the activation of naive and memory T cells. This leads to a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells, thereby killing cancer cells.
| Identifier | MLC-T-ONC-015668 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | oncolytic VSV-GP-huCD80Fc BI 1821736; VSV-GP BI 1821736 |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-015668",
"term": "oncolytic VSV-GP BI 1821736",
"field": "Oncology and biomedicine",
"definition": "An oncolytic virus derived from the vesicular stomatitis virus (VSV), a single-stranded RNA virus, and containing a genetically modified glycoprotein (GP) and a human CD80 (B7.1) Fc fragment, with potential immunomodulating and antineoplastic activities. Upon administration, oncolytic VSV-GP BI 1821736 preferentially replicates in tumor cells, and induces VSV-mediated cytolytic activity towards the tumor cells. Viral infection also stimulates the immune system to recognize these same tumor cells, leading to immune-mediated killing of both infected and non-infected tumor cells, thereby further killing tumor cells. In addition, BI 1821736 secretes CD80, which targets and binds to CD28, and in the presence of antigenic T-cell receptor (TCR) signaling leads to the co-stimulation of T-cell responses including the activation of naive and memory T cells. This leads to a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells, thereby killing cancer cells.",
"synonyms": [
"oncolytic VSV-GP-huCD80Fc BI 1821736",
"VSV-GP BI 1821736"
],
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/oncolytic-vsv-gp-bi-1821736/"
}
Record 12,234 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.